Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study.

Autor: Moskalewicz A; St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, 155 College Street Suite 425, Toronto, ON M5T 3M6, Canada., Di Tomaso A; St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.; Mount Sinai Hospital, 1284-600 University Avenue, Toronto, ON M5G 1X5, Canada., Kachura JJ; Mount Sinai Hospital, 1284-600 University Avenue, Toronto, ON M5G 1X5, Canada., Scime S; St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada., Nisenbaum R; Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria Street, Toronto, ON M5B 1T8, Canada.; Dalla Lana School of Public Health, University of Toronto, 155 College Street 6th Floor, Toronto, ON M5T 3M7, Canada., Lee R; St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada., Haq R; St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada., Derzko C; St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada., Brezden-Masley C; St. Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8, Canada.; Mount Sinai Hospital, 1284-600 University Avenue, Toronto, ON M5G 1X5, Canada.; Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria Street, Toronto, ON M5B 1T8, Canada.; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, ON M5G 1X5, Canada.
Jazyk: angličtina
Zdroj: Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Mar 09; Vol. 29 (3), pp. 1813-1827. Date of Electronic Publication: 2022 Mar 09.
DOI: 10.3390/curroncol29030149
Abstrakt: Endocrine therapy (ET) for hormone receptor-positive (HR+) breast cancer can contribute to gynecologic symptoms (GS) that impact vaginal health, sexual function, and quality of life (QoL). A cross-sectional study was conducted at St. Michael's Hospital in Toronto, Canada between July 2017 and June 2018 to examine the occurrence and frequency of GS among HR+ breast cancer patients on ET, patient-provider communication, female sexual dysfunction (FSD), and QoL. A Treatment Experience questionnaire was developed for this study and the Female Sexual Function Index (FSFI) and Menopause-Specific Quality of Life questionnaire (MENQOL) were also administered. Of 151 patients surveyed, 77 (51.0%) were on tamoxifen and 74 (49.0%) on an aromatase inhibitor. Most patients (84.1%, 95% confidence interval [CI] 77.3% to 89.5%) experienced at least one GS "all the time" or "often", or one or more infections, in the past year. Only 44 (31.9%) patients reported that their oncologist had ever previously asked them about experiencing GS. The prevalence of FSD was 61.2% (95% CI 46.2% to 74.8%) among 49 sexually active patients that completed the FSFI. Symptoms captured in the MENQOL's vasomotor domain were deemed most bothersome. Side effect management and patient-provider communication should be prioritized to optimize GS, vaginal health, and sexual function of ET users.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje